Compass Therapeutics, Inc. has reported a notable stock acquisition by its Chief Accounting Officer, Neil Lerner. On November 17, 2026, Lerner purchased 10,000 shares of the company’s common stock at a price of $0.59 per share. This transaction is significant as it reflects Lerner's confidence in the company's future prospects within the biological products industry.
Compass Therapeutics, based in Boston, operates in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company trades under the ticker CMPX on the Nasdaq. Recent filings indicate that Compass Therapeutics is categorized as a smaller reporting company and is classified under SIC code 2836.
According to the SEC filing dated November 18, 2026, Lerner's acquisition of shares brings his total ownership to 430,000 shares, which includes 62,500 shares that are unvested restricted stock units (RSUs) granted earlier this year. These RSUs are set to vest in four equal annual installments, with the first installment expected to vest on January 2, 2027. The filing stated, "Neil Lerner acquired 10,000 shares of common stock on November 17, 2026, at a price of $0.59 per share."
This acquisition may impact various stakeholders, including investors and employees. Lerner's investment could be seen as a positive signal to investors about the company's direction and potential growth in the competitive biological products market. The fact that Lerner is an officer of the company suggests that he has insights into the company's operations and future plans.
The filing does not specify what actions will follow this acquisition, leaving the future direction of Compass Therapeutics open to speculation.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





